Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
The new hospital is expected to open by March'24
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
Subscribe To Our Newsletter & Stay Updated
